Background The two available drugs for treatment of T. cruzi infection, nifurtimox and
benznidazole (BZ), have potential toxic side effects and variable efficacy, contributing to their …

Novel technologies that include recombinant pathogens and rapid detection methods are
contributing to the development of drugs for neglected diseases. Recently, the results from …

The discovery of new therapeutic options against Trypanosoma cruzi, the causative agent of
Chagas disease, stands as a fundamental need. Currently, there are only two drugs …

Background Chagas disease, caused by the protozoan parasite Trypanosoma cruzi,
represents a very important public health problem in Latin America where it is endemic …

Chagas' disease, caused by infection with the parasite Trypanosoma cruzi, is the major
cause of heart failure in Latin America. Classic clinical manifestations result from the …

Background: Strategies for development of anti-parasite chemotherapy involve identification
of active principles of plants, investigation of drugs already licensed for other pathologies, or …

Chagas' disease is responsible for significant mortality and morbidity in Latin America.
Current treatments display variable efficacy and have adverse side effects, hence more …

In the 100 years since the discovery of Chagas disease, only two drugs have been
developed and introduced into clinical practice, and these drugs were introduced over 40 …

An estimated 8 million persons, mainly in Latin America, are infected with Trypanosoma
cruzi, the etiologic agent of Chagas disease. Existing antiparasitic drugs for Chagas disease …

Chagas disease, a neglected illness, affects nearly 12-14 million people in endemic areas of
Latin America. Although the occurrence of acute cases sharply has declined due to …